Item 8.01 Other Events.
Propanc Biopharma Inc. (the "Company") has retired its final convertible
promissory note, dated June 30, 2022 (the "Note"), in favor of 1800 Diagonal
Lending LLC (the "Holder"). The Note was previously disclosed in the Company's
Current Report on Form 8-K filed on July 7, 2022.
On February 15, 2023, the Company initiated and made full and final payment of
the Note, fully converting all outstanding principal and interest into shares of
the Company's common stock, leaving a zero balance remaining. Accordingly, the
parties have no further rights or obligations as to each other as to the debt
that had been memorialized by the Note, and the Company does not have any
remaining obligations to issue any of its securities to the Holder.
Note: the information in this Current Report (including any exhibits) shall not
be deemed to be "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the
liabilities of that section, or incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a filing. This Current Report
will not be deemed a determination or an admission as to the materiality of any
information in the report that is required to be disclosed solely by Regulation
FD.
© Edgar Online, source Glimpses